Klinische Studie

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer(V940-002)Phase 3 study of Adjuvant V940 and Pembrolizumab in Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
EUDRACT2023-504923-20
NCTNCT06077760
DRKS-
Krankheitsentität(en) Lunge
StudientypInterventionsstudiePhase III
Wesentliche EinschlusskriterienR0 resected Stage II/IIIA/IIIB NSCLC 18 Years
Wesentliche AusschlusskriterienPrior neoadjuvant therapy Received prior radiotherapy
Statusrekrutierend
Ansprechpartner & KontaktUniversitätsklinikum RegensburgInnere Medizin IIStudienzentrale0941 9444475pneumologie.studienzentrum(at)ukr.de
zurück